Life sciences companies that turned outbound into a growth engine

A multinational bioprocess equipment manufacturer had a specialized aseptic filling product line with no dedicated outbound sales motion. Their BD team was stretched thin — handling inbound leads, existing customer relationships, and technical conversations — leaving no capacity for systematic prospecting. The product was highly technical (robotic, gloveless isolator-based filling systems), the buyer personas were niche (VP/Director-level operations and engineering at CDMOs and emerging biotech/pharma), and sales cycles typically stretched 12–18 months.

We embedded as an extension of their commercial team for 11 months, executing multi-channel outbound across LinkedIn, cold calling, personalized email, and executive LinkedIn content. We built their outreach infrastructure from scratch — domains, inboxes, CRM, tool stack — and managed all campaign execution including list building, messaging development, reply monitoring, and conference pre-booking.

• Secured meetings with VPs of Manufacturing and SVPs of Process Development at major CDMOs and pharma companies
• Converted a cold LinkedIn connection into a scheduled in-person meeting with a leading European CDMO
• Generated an inbound RFQ from a gene therapy company requesting a configured system quote — catalyzed by outbound awareness efforts
• Multiple referral chains that reached the right stakeholders (e.g., referral from EVP → Engineering Head → scheduled meeting at a major EPC firm)
• Mapped competitive positioning — identified which prospects used competing systems, satisfaction levels, and switching triggers
• Positioned the client's BD reps as recognized thought leaders in aseptic filling compliance and technology through executive LinkedIn content

A life science data and intelligence platform had strong inbound traction and product-market fit but had never built a systematic outbound sales motion. Their target buyers — Heads of Business Development, Competitive Intelligence directors, and Portfolio Strategy leaders at mid-to-large pharma and biotech companies — were difficult to reach through digital channels alone. The platform competed in a crowded space alongside established tools, and the team needed to quickly validate whether cold outbound could open doors at enterprise pharma accounts.

We launched a combined cold calling and LinkedIn campaign, supplemented by targeted conference pre-booking for a major European partnering conference. Over 3 months, we placed 3,000+ calls with connect rates ranging from 1.5% to 10.7%, developed and iterated cold call scripts with objection handling, and trained a dedicated cold caller alongside founder-led calling to significantly increase throughput.

• Generated meeting requests and positive engagement from decision-makers at multiple top-10 global pharma companies, including Directors of Competitive Intelligence, SVPs of Licensing & Acquisitions, and Heads of Portfolio Strategy
• A Global Head of Portfolio Strategy at a top-5 pharma expressed surprise they weren't already a customer — noting strong familiarity with the platform
• Secured meetings with Directors of BD at multiple mid-cap and specialty pharma companies actively evaluating competitive intelligence platforms
• Through targeted pre-conference calling, generated 15+ confirmed or pending meetings at a major European partnering conference through the official partnering platform
• Multiple Director and VP-level contacts at large pharma requested platform details, differentiator overviews, and use case examples for internal review and team distribution

A laboratory informatics startup had built a platform that helps bioprocess and manufacturing teams centralize data from disparate systems and perform root cause analysis without manually exporting to spreadsheets. The product solved a real pain point, but the company had never executed cold outbound at scale. Their pipeline came from warm introductions and inbound interest. They needed to test whether cold outreach — particularly cold calling — could open doors with Director and VP-level buyers, while also gathering market intelligence on how companies currently handle their data.

We onboarded in under one week and launched a combined LinkedIn and cold calling campaign across four sender profiles, with a North America and Europe split. We built prospect lists totaling 400+ contacts across biotech, pharma, and CDMOs, segmented by account ownership to maintain relationship continuity, and prioritized named accounts including a leading mRNA therapeutics company and a major plasma-derived therapeutics manufacturer.

• Multiple Directors at a leading mRNA therapeutics company engaged across LinkedIn, with contacts sharing information with their internal technical teams
• Positive conversations with prospects at a leading gene editing therapeutics company, a clinical-stage ADC biotech, and a major rare disease therapeutics company
• Multiple prospects independently confirmed they export to spreadsheets to compare runs across systems — validating the exact pain point the platform solves
• VP-level sender profile achieved 37% LinkedIn connection acceptance rate vs. 4–12% for junior profiles — confirming that in technical B2B, prospects connect with peers